Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Medifast Q2 Earnings Call Highlights
Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter.
Medifast (MED) Reports Q2 Loss, Beats Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $0.04 per share a year ago.
Medifast Stock to Post Q2 Earnings: What Investors Should Know
MED's Q2 results are likely to face continued pressure from GLP-1 adoption and a smaller coach base, while productivity gains and cost actions may have helped offset some challenges.
Medifast (MED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Medifast (MED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Medifast's Trilivy Launch Unlock a New Growth Chapter?
Medifast's Trilivy expands beyond weight management with metabolic health support, personalized coaching and a structured three-phase journey.
Medifast (MED) Loses 18.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Medifast (MED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Medifast (MED) Down 5.1% Since Last Earnings Report: Can It Rebound?
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Is MEDIFAST (MED) Stock Outpacing Its Consumer Staples Peers This Year?
Here is how Medifast (MED) and New York Times Co. (NYT) have performed compared to their sector so far this year.
Why Medifast's $15 Cash Per Share Makes It A Strong Buy
Medifast trades below net cash value, with $15 per share in cash versus a $12.60 share price, creating a compelling value floor. Coach productivity surged 19% YoY to $5,432 per coach, signaling early signs of operational turnaround despite a shrinking coach base. Cost-cutting initiatives, asset sales, and a positive operating cash flow position MED for potential profitability by Q4 2026, with a $30 million savings target.
Medifast: Worth Putting On A Watchlist
Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.50 if the company's earnings stabilize over the mid-term. Such upside is speculative, though.
Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
MED beats first-quarter estimates despite steep revenue declines, while stronger coach productivity and a new product launch support recovery hopes.
